At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 17 enrolled
Drug / intervention
TILT-123biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Dose-Escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 in Melanoma Patients Receiving Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes
In Brief
A Phase 1 clinical trial evaluating TILT-123 for Metastatic Melanoma. Completed, enrolled 17 participants across 2 sites in 2 countries.
Detailed Summary
This is an open-label, phase 1, first-in-human (FIH), dose-escalation, multicenter, multinational trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy and in association with T-cell therapy with TILs in metastatic melanoma patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Melanoma
CountriesDenmark, France
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartFeb 2020
Primary CompletionDec 2023
Study CompletionJul 2024
TodayJul 2026
First PostedJan 3, 2020
Enrollment StartFeb 26, 2020
Primary CompletionDec 12, 2023
Study CompletionJul 23, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.5 years ago
Interventions
TILT-123biological
TNFalpha and IL-2 coding oncolytic adenovirus TILT-123